181 related articles for article (PubMed ID: 25579848)
21. Formulation, in vitro characterization and optimization of taste-masked orally disintegrating co-trimoxazole tablet by direct compression.
Tafere C; Yilma Z; Abrha S; Yehualaw A
PLoS One; 2021; 16(3):e0246648. PubMed ID: 33725014
[TBL] [Abstract][Full Text] [Related]
22. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
Mostafa HF; Ibrahim MA; Sakr A
Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
[TBL] [Abstract][Full Text] [Related]
23. Development and evaluation of cetirizine HCl taste-masked oral disintegrating tablets.
Douroumis DD; Gryczke A; Schminke S
AAPS PharmSciTech; 2011 Mar; 12(1):141-51. PubMed ID: 21181510
[TBL] [Abstract][Full Text] [Related]
24. Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion.
Gryczke A; Schminke S; Maniruzzaman M; Beck J; Douroumis D
Colloids Surf B Biointerfaces; 2011 Sep; 86(2):275-84. PubMed ID: 21592751
[TBL] [Abstract][Full Text] [Related]
25. Formulation and optimization of orally disintegrating tablets of sumatriptan succinate.
Sheshala R; Khan N; Darwis Y
Chem Pharm Bull (Tokyo); 2011; 59(8):920-8. PubMed ID: 21804234
[TBL] [Abstract][Full Text] [Related]
26. Desktop 3D printing of controlled release pharmaceutical bilayer tablets.
Khaled SA; Burley JC; Alexander MR; Roberts CJ
Int J Pharm; 2014 Jan; 461(1-2):105-11. PubMed ID: 24280018
[TBL] [Abstract][Full Text] [Related]
27. Preparation and evaluation of unpleasant taste-masked pioglitazone orally disintegrating tablets.
Nakano Y; Maeda A; Uchida S; Namiki N
Int J Pharm; 2013 Mar; 446(1-2):160-5. PubMed ID: 23419665
[TBL] [Abstract][Full Text] [Related]
28. Ultra-fast disintegrating ODTs comprising viable probiotic bacteria and HPMC as a mucoadhesive.
Hoffmann A; Daniels R
Eur J Pharm Biopharm; 2019 Jun; 139():240-245. PubMed ID: 30946916
[TBL] [Abstract][Full Text] [Related]
29. Comparative study of different approaches for preparation of chlorzoxazone orodispersible tablets.
Moqbel HA; ElMeshad AN; El-Nabarawi MA
Drug Dev Ind Pharm; 2017 May; 43(5):742-750. PubMed ID: 27534668
[TBL] [Abstract][Full Text] [Related]
30. Orally disintegrating tablet of novel salt of antiepileptic drug: formulation strategy and evaluation.
Rahman Z; Siddiqui A; Khan MA
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1300-9. PubMed ID: 23800704
[TBL] [Abstract][Full Text] [Related]
31. Formulating Amorphous Solid Dispersions: Impact of Inorganic Salts on Drug Release from Tablets Containing Itraconazole-HPMC Extrudate.
Takano R; Maurer R; Jacob L; Stowasser F; Stillhart C; Page S
Mol Pharm; 2020 Aug; 17(8):2768-2778. PubMed ID: 31794228
[TBL] [Abstract][Full Text] [Related]
32. The role of formulation excipients in the development of lyophilised fast-disintegrating tablets.
Chandrasekhar R; Hassan Z; Alhusban F; Smith AM; Mohammed AR
Eur J Pharm Biopharm; 2009 May; 72(1):119-29. PubMed ID: 19073253
[TBL] [Abstract][Full Text] [Related]
33. Orodispersible tablets containing taste-masked solid lipid pellets with metformin hydrochloride: Influence of process parameters on tablet properties.
Petrovick GF; Kleinebudde P; Breitkreutz J
Eur J Pharm Biopharm; 2018 Jan; 122():137-145. PubMed ID: 29106946
[TBL] [Abstract][Full Text] [Related]
34. Development and optimization of lyophilized orally disintegrating tablets using factorial design.
Ahmed IS; Shamma RN; Shoukri RA
Pharm Dev Technol; 2013; 18(4):935-43. PubMed ID: 22107175
[TBL] [Abstract][Full Text] [Related]
35. Development of Tablet Formulation of Amorphous Solid Dispersions Prepared by Hot Melt Extrusion Using Quality by Design Approach.
Agrawal A; Dudhedia M; Deng W; Shepard K; Zhong L; Povilaitis E; Zimny E
AAPS PharmSciTech; 2016 Feb; 17(1):214-32. PubMed ID: 26757898
[TBL] [Abstract][Full Text] [Related]
36. Preparation and evaluation of taste-masked donepezil hydrochloride orally disintegrating tablets.
Yan YD; Woo JS; Kang JH; Yong CS; Choi HG
Biol Pharm Bull; 2010; 33(8):1364-70. PubMed ID: 20686233
[TBL] [Abstract][Full Text] [Related]
37. Investigation of Filler Effects on the Compounding of Freeze-dried Orodispersible Tablets Containing Annona muricata Extract.
Azman SEN; Abd Razak FS; Kamal WHBW; Zheng GK; Ming LC; Uddin AH; Sarker ZI; Bin LK
Int J Pharm Compd; 2020; 24(6):509-514. PubMed ID: 33217741
[TBL] [Abstract][Full Text] [Related]
38. Development and optimization of levodopa and benzylhydrazine orally disintegrating tablets by direct compression and response surface methodology.
Zhang Y; Li Z; Tang H; Ren W; Gao X; Sun Y; Zhao QX; Wang F; Liu J
Drug Dev Ind Pharm; 2020 Jan; 46(1):42-49. PubMed ID: 31794271
[TBL] [Abstract][Full Text] [Related]
39. Comparison of release-controlling efficiency of polymeric coating materials using matrix-type casted films and diffusion-controlled coated tablet.
Piao ZZ; Lee KH; Kim DJ; Lee HG; Lee J; Oh KT; Lee BJ
AAPS PharmSciTech; 2010 Jun; 11(2):630-6. PubMed ID: 20373152
[TBL] [Abstract][Full Text] [Related]
40. Optimization of taste-masked dapoxetine oral thin films using factorial design:
El-Said IA; Aboelwafa AA; ElGazayerly ON
Pharm Dev Technol; 2021 Jun; 26(5):522-538. PubMed ID: 33663316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
